RecruitingNCT05599412
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Lorviqua (Registered)
Sponsor
Pfizer
Enrollment
600 participants
Start Date
May 22, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This post-market surveillance study monitors real-world use of lorlatinib (brand name Lorviqua) in adult patients with a specific type of advanced lung cancer in South Korea. The study collects safety and effectiveness data as the drug is used in routine clinical practice.
**You may be eligible if...**
- You are an adult being treated with lorlatinib for ALK-positive metastatic non-small cell lung cancer (NSCLC)
- You have provided written informed consent
**You may NOT be eligible if...**
- You are not being treated with lorlatinib as part of your standard care
- You do not have the ALK gene mutation in your lung cancer
- You are under 18 years old
Talk to your doctor to see if this trial is right for you.
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLorviqua
As provided in real world practice
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05599412